Agile Sciences-Breaking the Cycle of Antibiotic Resistance

The 2-AI compounds developed by Agile Sciences do not kill bacteria but act by inhibiting the internal bacterial defense mechanism known as the Two-Component system (TCS). This inhibition prevents the bacteria from forming biofilms, producing toxins and developing resistance thus allowing antibiotics do their job more efficiently. As an example, Malcolm Thomas cites the work done by Agile Sciences in treating Cystic Fibrosis (CF): “in an animal model, we have seen marked improvement in the treatment of lung infections in CF, where an inhaled form of our compound disperses the biofilm that forms in the lungs resulting in the use of significantly less antibiotic to achieve clearance.”

The 2 AI compounds work not only with currently used antibiotics, but they are effective in re-activating older antibiotics. “These compounds re-potentiate older antibiotics that have been rendered useless by resistance as well as extend the useful life of current antibiotics,” says Thomas.

Agile Sciences will be presenting their research at the 5^th One Health Congress in Saskatoon, Canada on Sunday June 24th 2018.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005032/en/